© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Delivering Personalized Medicine Through Molecular Diagnostics and Innovation
Posted 30th August 2019

Delivering Personalized Medicine Through Molecular Diagnostics and Innovation

Interpace Diagnostics provides molecular tests and pathology services to physicians and hospitals for various types of cancer. Earlier this year, the company found success in AI’s Global Excellence Awards 2019 where they were selected as the Most Innovative Molecular Diagnostics Company 2019 – Northeast USA.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Delivering Personalized Medicine Through Molecular Diagnostics and Innovation
team

Delivering Personalized Medicine Through Molecular Diagnostics and Innovation

Interpace Diagnostics provides molecular tests and pathology services to physicians and hospitals for various types of cancer. Earlier this year, the company found success in AI’s Global Excellence Awards 2019 where they were selected as the Most Innovative Molecular Diagnostics Company 2019 – Northeast USA. Following this win, we caught up with Chief Commercial Officer, Greg Richard who kindly provided us with a glimpse into the award-winning services the team consistently delivers.

Since their inception, Interpace Diagnostics has developed and commercialized molecular diagnostics tests for early detection of cancer in lesions where risk is uncertain by routine clinical methods. Today, Interpace Diagnostics currently has five marketed products for various indications: ThyGeNEXT, ThyraMIR, PancraGEN, RespriDx and BarreGEN. Going into further detail, Greg begins by informing us of the key qualities of each of these products and explaining what each one is used for.

“ThyGeNEXT and ThyraMIR are used to determine whether or not a patient has risk factors for thyroid cancer; it helps assist physicians in making decisions regarding surgical intervention. PancraGEN, the company’s pancreatic cancer risk classifier, is performed on an integrated molecular pathology platform and assists physicians in identifying those patients with pancreatic cysts, solid lesions, and biliary strictures that are at risk of developing pancreatic or biliary cancer. PancraGEN has been used in over 40,000 patient samples and represents the largest data repository of molecular data on pancreatic cysts in the U.S. RespriDx is used to differentiate new lung tumors from those that represent metastasis from other organs to help drive therapeutic decision making. Finally, BarreGEN is used to evaluate mutational load in samples taken from the esophagus to identify patients that are at risk of progressing to esophageal cancer.” As for how these products are implemented and which industry experts the Interpace Diagnostics team approaches, Greg touches on the services and experiences each leader brings to the table and how they use the firm’s products.

“For our Thyroid products, ThyGeNEXT and ThyraMIR, we call primarily on Endocrinologists, ENT’s, Pathologists, Endocrine Surgeons, and Otolaryngologists. We approach them directly via our own Commercial team; identifying them from industry trade conferences and specialty physician databases.

“For pancreatic cancer, we call on Gastroenterologists and specifically those that perform Endoscopic Ultrasound Fine Needle Aspirates of the pancreas. These ‘Endoscopists’ are the primary source of our samples for molecular testing of pancreatic neoplasms. Additionally, we work closely with Pathologists who often perform routine first line tests prior to reflexing to molecular testing and PancraGEN. For BarreGEN, we essentially call on the same constituencies given that the procedure to collect the sample is similar to that used for PancraGEN. For RespriDX, we call on Thoracic Surgeons and Oncologists who focus on Lung cancer as a specialty within the overall oncology market.”

Overall the firm’s mission is to provide important supplemental information following common first line tests to help mitigate diagnostic uncertainty. Providing the firm with the ability and opportunity to fulfil this mission is the innovative, committed and passionate team which forms the backbone of Interpace Diagnostics. When discussing the internal culture, Greg is keen to highlight the significant role the teams play in the overall success of the firm.

“All 100 members of our team are critical to the success of the Company; from our lab Operations team to Client Services, Commercial, and our Corporate Leadership team, we are all focused on our primary mission – to eliminate diagnostic uncertainty and improve patient care and outcomes. We often recognize individuals and teams for extraordinary performance or contributions to a particular focus or priority for the Company.”

Looking ahead to what the future holds for the firm, the team at Interpace Diagnostics hope to build upon their advancements within the industry and their accomplishments, especially following their recent success in Acquisition Intl.’s (AI) Global Excellence Awards 2019 where they were righteously awarded the accolade Most Innovative Molecular Diagnostics Company 2019 – Northeast USA. Bringing the interview to a close, Greg signs off by revealing the exciting plans which lie in the pipeline for the firm, noting how the company will complete clinical studies and publish papers in the years to come.

“Moving forward, we will be launching product extensions and expanding indications for some of our current products. In addition, we are starting large-scale studies that will further validate our current products. Lastly, we will also be publishing papers in peer-reviewed publications and will be speaking at and participating in several key industry sponsored conferences including the American Thyroid Association and the American College of Gastroenterology.”

Ultimately, Interpace Diagnostics is consistently growing and at a rapid rate. The future looks promising for the company as they continue to dedicate their time and services to improving patient care through unparalleled insights which have been provided by their proprietary suite of products. As such, Interpace Diagnostics’ success has been a result of the confidence that their customers have in that information.

Company: Interpace Diagnostics

Web Address: www.interpacediagnostics.com

Categories: Innovation


You Might Also Like
Read Full PostRead - Eye Icon
I Have a Unique Business. Can a Buyer Be Found?
News
07/11/2022I Have a Unique Business. Can a Buyer Be Found?

Putting your business on the market for sale is a considerable undertaking, regardless of its uniqueness. This is why it's essential to avoid the mistake of selling your business to the first investor or company that makes an offer. The search for the ideal bu

Read Full PostRead - Eye Icon
Ruling Over the World’s Economies
Innovation
06/11/2015Ruling Over the World’s Economies

Developing economies quickened the pace of their business reforms during the last 12 months to make it easier for local businesses to start and operate, says the World Bank Group’s annual ease of doing business measurement.

Read Full PostRead - Eye Icon
Third Quarter Update
Legal
02/02/2016Third Quarter Update

DN Legal is a legal firm dedicated to providing bespoke legal services tailored to the client’s individual needs.

Read Full PostRead - Eye Icon
Bulge Bracket Banks Increased their M&A Advisory Market Share in 2015’s Record-Breaking Merger Spree
Finance
02/03/2016Bulge Bracket Banks Increased their M&A Advisory Market Share in 2015’s Record-Breaking Merger Spree

The largest investment banks notched a 20% gain in market share of the US M&A advisory market during last-year’s record-breaking technology M&A spree, according to a new report by 451 Research.

Read Full PostRead - Eye Icon
How Digital Magazine Marketing Strategies Help Your Business Reach the Maximum Audience
News
11/01/2024How Digital Magazine Marketing Strategies Help Your Business Reach the Maximum Audience

How Digital Magazine Marketing Strategies Help Your Business Reach the Maximum Audience Today’s digitally-driven world offers a creative and practical way to reach a large audience: digital magazine marketing. This marketing tactic makes digital magazine

Read Full PostRead - Eye Icon
Resolution Insurance Majority Stake Acquisition
Finance
19/03/2015Resolution Insurance Majority Stake Acquisition

LeapFrog Investments, the private equity firm with a focus on Africa and Asia, said it will pay 1.68 billion shillings ($19 million) to gain control of Kenya’s Resolution Insurance and tap growth in health coverage.

Read Full PostRead - Eye Icon
Sierra Nevada Corporation Acquires Kutta Technologies, Inc. to Expand its Unmanned Technologies
M&A
29/04/2015Sierra Nevada Corporation Acquires Kutta Technologies, Inc. to Expand its Unmanned Technologies

Sierra Nevada Corporation (SNC) announces the successful acquisition of its newest wholly-owned subsidiary, Kutta Technologies, Inc. (Kutta) located in Phoenix, Arizona.

Read Full PostRead - Eye Icon
AVIC Acquires Fourth US Aviation Firm
M&A
15/04/2015AVIC Acquires Fourth US Aviation Firm

The Aviation Industry Corporation of China (AVIC) has completed the acquisition of US company Align Aerospace, it was announced on 10 April.

Read Full PostRead - Eye Icon
The Future of Trading Has Arrived: Say Hello to Tradu
Finance
30/11/2023The Future of Trading Has Arrived: Say Hello to Tradu

Tradu is an innovative new trading platform backed by leading global investment firm, Jeffries, offering users a seamless multi-asset trading experience.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow